• Puromycin Aminonucleoside: Precision Podocyte Injury Modelin

  2026-05-09

  Puromycin aminonucleoside enables reproducible induction of nephrotic syndrome in animal and cell-based models, offering unmatched control over the study of podocyte injury and glomerular lesion formation. This guide details experimental workflows, troubleshooting strategies, and the latest innovations—positioning APExBIO’s product as the gold-standard tool for renal pathophysiology research.

• Acetylcholine Chloride in Gut-Brain Axis Research: Mechanist

  2026-05-08

  Explore how Acetylcholine Chloride enables cutting-edge research into cholinergic signaling in the gut-brain axis. This article reveals practical assay guidance and translational relevance, setting it apart with a mechanistic and application-focused perspective.

• Improving In Vitro Drug Response Evaluation in Cancer Resear

  2026-05-08

  Schwartz's dissertation advances the assessment of anti-cancer drugs by distinguishing between proliferative arrest and cell death in in vitro assays, revealing nuanced drug effects on cancer cells. These methodological refinements have direct implications for evaluating agents like chlorambucil and optimizing cytotoxicity assays in cancer research.

• DrPISA Workflow: Enhanced Drug Target Profiling via DES-48 P

  2026-05-07

  The DrPISA method integrates deep eutectic solvent (DES-48) into a reverse proteome-integrated solubility alteration framework, significantly improving the identification of drug–protein interactions from heat-aggregated proteomes. This high-sensitivity approach expands target coverage beyond traditional soluble-focused assays, offering new insights into protein stability and drug mechanism research.

• PP2A-Mediated Autophagy Drives Candida albicans Biofilm Drug

  2026-05-07

  This study uncovers how protein phosphatase 2A (PP2A) regulates autophagy-related protein phosphorylation to enhance Candida albicans biofilm formation and antifungal drug resistance. By dissecting the molecular pathway through ATG protein modulation, the research provides an actionable target for overcoming biofilm-associated resistance in clinical settings.

• Hoechst 33342: Nuclear Staining for Precision Cell Analysis

  2026-05-06

  Hoechst 33342 stands out as an advanced bis-benzimidazole fluorescent dye for high-contrast, live-cell nuclear staining, enabling robust cell cycle and apoptosis assays. This guide details stepwise workflows, troubleshooting strategies, and practical innovations inspired by recent disease-modeling research.

• Spiroplasma eriocheiris Entry: Clathrin-Dependent and Macrop

  2026-05-06

  Wei et al. (2019) elucidate the cellular entry mechanism of Spiroplasma eriocheiris in Drosophila S2 cells, demonstrating reliance on clathrin-mediated endocytosis and macropinocytosis. Their inhibitor-based approach provides a robust framework for dissecting host-pathogen interactions in invertebrate models, with practical implications for endocytosis research and infectious disease studies.

• Ziprasidone Hydrochloride (A5350): Reliable Assays for Cance

  2026-05-05

  This article delivers scenario-driven guidance for researchers and technicians integrating Ziprasidone Hydrochloride (SKU A5350) into cell viability, proliferation, and cytotoxicity assays. Drawing on quantitative evidence and workflow best practices, it addresses reproducibility, assay optimization, and vendor reliability—demonstrating how this reagent supports sensitive and interpretable data in cancer and neuroscience research.

• Cediranib (AZD2171): Advanced Strategies for VEGFR Pathway R

  2026-05-05

  Cediranib (AZD2171) empowers cancer researchers to dissect VEGFR signaling with unmatched potency and selectivity. This guide delivers actionable protocols, troubleshooting insights, and comparative advantages rooted in recent in vitro evaluation breakthroughs.

• FXR-KLF11 Axis: CDCA’s Mechanistic Role in CI-AKI Protection

  2026-05-04

  This study identifies the FXR-KLF11 axis as central to the protective effects of Chenodeoxycholic Acid (CDCA) against contrast-induced acute kidney injury (CI-AKI). By demonstrating that CDCA-driven FXR activation transcriptionally upregulates KLF11, which in turn suppresses the JAK2/STAT3 pathway, the research advances mechanistic understanding and informs future prophylactic strategies for kidney injury.

• Toremifene vs Tamoxifen: Evidence for Advanced Breast Cancer

  2026-05-04

  The Cochrane review by Mao et al. provides a rigorous comparative analysis of toremifene and tamoxifen for advanced breast cancer, synthesizing randomized controlled trials to evaluate efficacy and safety. This evidence-driven synthesis informs treatment selection and highlights the need for nuanced protocol design in translational oncology.

• Lamotrigine in Mechanistic Neurocardiac Research: Beyond Epi

  2026-05-03

  Explore the advanced applications of Lamotrigine as a sodium channel blocker and 5-HT inhibitor in neurocardiac research. This article uniquely analyzes mechanistic insights and translational considerations for Lamotrigine, providing deeper scientific context than standard epilepsy-focused guides.

• LY2603618: Chk1 Inhibitor Workflows for Enhanced DNA Damage

  2026-05-02

  LY2603618 from APExBIO stands out as a highly selective Chk1 inhibitor, empowering researchers to dissect DNA damage response mechanisms and synergize chemotherapy regimens, especially in non-small cell lung cancer models. Discover stepwise protocols, troubleshooting insights, and real-world applications that maximize reproducibility and performance in advanced oncology workflows.

• Trelagliptin Enhances Osteoblastic Differentiation via RUNX2

  2026-05-01

  The referenced study establishes that Trelagliptin, a DPP-4 inhibitor typically used in diabetes, directly enhances osteoblastic differentiation through RUNX2 upregulation and AMPK signaling in MC3T3-E1 cells. These findings suggest a novel therapeutic avenue for osteoporosis and inform translational workflows requiring precise cell-type isolation.

• ER-Fusogenic Immunogenic Liposomes Enhance Anti-Tumor Immuni

  2026-05-01

  This study introduces phosphatidylinositol-based immunogenic nanoliposomes (PI-INLs) that activate dendritic cells and directly deliver antigens to the endoplasmic reticulum, dramatically boosting CD8 T cell responses in anti-tumor vaccination. The dual-action design addresses the limitations of conventional adjuvants and points to a promising platform for self-adjuvanting nanovaccines.

15595 records 1/1040 page Next 12345 下5页 Last page